Sandra Levy
ARTICLES BY THIS AUTHOR
- 8/25/2024
How do consumers define loyalty?
"Good value" and "trusted brand" topped the drivers of brand loyalty, per 84.51°'s August Consumer Digest. - 8/25/2024
TeleVox expands Agent Chat functionality to reduce inbound call volumes
Agent Chat utilizes a secure, web-based experience to connect patients to a staff member who can address the patient’s needs. - 8/25/2024
FTC trial over Kroger-Albertsons merger begins
The U.S. Federal Trade Commission’s lawsuit to block Kroger-Albertson’s merger went to trial today in federal court in Portland, Ore. - 8/25/2024
Boogie Board’s VersaNotes debut at CVS
Boogie Board created a specialized duo starter pack for CVS, including two reusable notes and a VersaPen, the writing tool that writes on and erases the notes. - 8/25/2024
Patrick Soon-Shiong joins Avenacy
Soon-Shiong brings more than 25 years of pharmaceutical industry experience, including successful commercialization of injectable generic drugs. - 8/25/2024
Lupin obtains Health Canada approval for Neulasta biosimilar
Pegfilgrastim prefilled syringes are indicated to decrease the incidence of infection in certain cases. - 8/22/2024
Which pharmacies are consumers shopping the most?
Coresight Research’s latest report found that 76.8% of U.S. consumers bought products from drugstores or pharmacy retailers in the past three months. - 8/22/2024
Biosimilars Council submits comments, applauds FDA Draft Guidance regarding interchangeability
The Biosimilars Council agrees with the FDA's position that data from a switching study or studies may no longer be necessary to support licensure of interchangeable biosimilar medicines. - 8/22/2024
ADS partners with StrideMD to launch program for diabetes management
The new program, StrideForward, offers integrated team and remote care services supporting diabetes management plans. - 8/22/2024
FTC submits comment supporting proposed FDA Guidance on interchangeable biosimilar drugs
The Guidance would support biologic drug competition, increase patient access to biosimilars and lower healthcare costs for patients, the FTC’s comment says.
